Show simple item record

dc.contributor.authorCubero-Millán, Isabel
dc.contributor.authorMolina-Carballo, Antonio
dc.contributor.authorMachado-Casas, Irene
dc.contributor.authorFernández-López, Luisa
dc.contributor.authorMartínez-Serrano, Sylvia
dc.contributor.authorTortosa-Pinto, Pilar
dc.contributor.authorRuiz-López, Aida
dc.contributor.authorLuna del Castillo, Juan de Dios
dc.contributor.authorUberos, José
dc.contributor.authorMuñoz-Hoyos, Antonio
dc.date.accessioned2014-11-13T07:53:57Z
dc.date.available2014-11-13T07:53:57Z
dc.date.issued2014
dc.identifier.citationCubero-Millán, I.; et al. Methylphenidate Ameliorates Depressive Comorbidity in ADHD Children without any Modification on Differences in Serum Melatonin Concentration between ADHD Subtypes. International Journal of Molecular Sciences, 15(9): 17115-17129 (2014). [http://hdl.handle.net/10481/33677]es_ES
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/10481/33677
dc.description.abstractThe vast majority of Attention-deficit/hyperactivity disorder (ADHD) patients have other associated pathologies, with depressive symptoms as one of the most prevalent. Among the mediators that may participate in ADHD, melatonin is thought to regulate circadian rhythms, neurological function and stress response. To determine (1) the serum baseline daily variations and nocturnal excretion of melatonin in ADHD subtypes and (2) the effect of chronic administration of methylphenidate, as well as the effects on symptomatology, 136 children with ADHD (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision: DSM-IV-TR criteria) were divided into subgroups using the “Children’s Depression Inventory” (CDI). Blood samples were drawn at 20:00 and 09:00 h, and urine was collected between 21:00 and 09:00 h, at inclusion and after 4.61 ± 2.29 months of treatment. Melatonin and its urine metabolite were measured by radioimmunoassay RIA. Factorial analysis was performed using STATA 12.0. Melatonin was higher predominantly in hyperactive-impulsive/conduct disordered children (PHI/CD) of the ADHD subtype, without the influence of comorbid depressive symptoms. Methylphenidate ameliorated this comorbidity without induction of any changes in the serum melatonin profile, but treatment with it was associated with a decrease in 6-s-melatonin excretion in both ADHD subtypes. Conclusions: In untreated children, partial homeostatic restoration of disrupted neuroendocrine equilibrium most likely led to an increased serum melatonin in PHI/CD children. A differential cerebral melatonin metabolization after methylphenidate may underlie some of the clinical benefit.es_ES
dc.description.sponsorshipFunding for this study was provided by the Health Research Fund (Fondo de Investigaciones sanitarias (FIS); Spanish Ministry of Science and Innovation), FIS-PI07-0603.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 3.0 Licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es_ES
dc.subjectChildrenes_ES
dc.subjectADHDes_ES
dc.subjectADHD subtypeses_ES
dc.subjectComorbiditieses_ES
dc.subjectDepressive symptomses_ES
dc.subjectCDIes_ES
dc.subjectProlonged release methylphenidatees_ES
dc.subjectMelatonines_ES
dc.subject6-sulphatoxy-melatonines_ES
dc.titleMethylphenidate Ameliorates Depressive Comorbidity in ADHD Children without any Modification on Differences in Serum Melatonin Concentration between ADHD Subtypeses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/ijms150917115


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Except where otherwise noted, this item's license is described as Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License